Colorectal liver metastases: Contrast agent diffusion coefficient for quantification of contrast enhancement heterogeneity at MR imaging

Radiology

Volumn 248, Issue 3, 2008, Pages 901-909

  Jia, Guang ^a   O'Dell, Craig ^a   Heverhagen, Johannes T ^a   Yang, Xiangyu ^a   Liang, Jiachao ^a   Jacko, Richard V ^a   Sammet, Steffen ^a   Pellas, Theodore ^b   Cole, Patricia ^b   Knopp, Michael V ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; GADOLINIUM PENTETATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CONVALESCENCE; CORRELATION COEFFICIENT; DIFFUSION COEFFICIENT; FEMALE; HUMAN; INFORMED CONSENT; INSTITUTIONAL REVIEW; LINEAR REGRESSION ANALYSIS; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; RETROSPECTIVE STUDY; STATISTICAL MODEL; COLORECTAL TUMOR; COMPUTER ASSISTED DIAGNOSIS; IMAGE ENHANCEMENT; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

AGED; COLORECTAL NEOPLASMS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 51549083694     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2491071936     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Lise M, Mocellin S, Pilati P, Nitti D. Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches. Front Biosci 2005;10:3042-3057.
3. Nakayama M, Yamashita Y, Mitsuzaki K, et al. Improved tissue characterization of focal liver lesions with ferumoxide-enhanced T1 and T2-weighted MR imaging. J Magn Reson Imaging 2000;11:647-654.
4. Tanimoto A, Wakabayashi G, Shinmoto H, Okuda S, Kuribayashi S, Mukai M. The mechanism of ring enhancement in hepatocellular carcinoma on superparamagnetic iron oxide-enhanced T1-weighted images: an investigation into peritumoral Kupffer cells. J Magn Reson Imaging 2005;21:230-236.
5. Chung JJ, Kim MJ, Kim KW. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful? J Magn Reson Imaging 2006;23:706-711.
6. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 2005;5(spec no. A):S149-S156.
7. van Laarhoven HW, Rijpkema M, Punt CJ, et al. Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging 2003;18:315-320.
8. Marchal G, Ni Y, Van Damme B, et al. Role of contrast agent perfusion and of diffusion in the NMR signal enhancement of liver lesions. J Comput Assist Tomogr 1992;16:690-698.
9. Lee L, Sharma S, Morgan B, et al. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother Pharmacol 2006;57:761-771.
10. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-3964.
11. van Laarhoven HW, Klomp DW, Rijpkema M, et al. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 2007;20:128-140.
12. Del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 2002;225:766-772.
13. Kitajima K, Kuwata Y, Hayashi M, Imanaka K, Kaji Y, Sugimura K. Ring enhancement on T1-weighted GRE images after ferucarbotran administration for hepatic metastasis: comparison with pathological findings - case report. Radiat Med 2005;23:75-79.
14. Mitchell DG, Saini S, Weinreb J, et al. Hepatic metastases and cavernous hemangiomas: distinction with standard- and triple-dose gadoteridol-enhanced MR imaging. Radiology 1994;193:49-57.
15. Kim YK, Lee JM, Kim CS. Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions. Eur Radiol 2004;14:5-13.
16. Yu JS, Rofsky NM. Hepatic metastases: perilesional enhancement on dynamic MRI. AJR Am J Roentgenol 2006;186:1051-1058.
17. Naganawa S, Kawai H, Fukatsu H, et al. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future. Magn Reson Med Sci 2005;4:175-186.
18. Sehy JV, Ackerman JJ, Neil JJ. Evidence that both fast and slow water ADC components arise from intracellular space. Magn Reson Med 2002;48:765-770.
19. Fong Y. Surgical therapy of hepatic colorectal metastasis. CA Cancer J Clin 1999;49:231-255.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
21. Jia G, Heverhagen JT, Henry H, et al. Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI. Magn Reson Imaging 2006;24:721-725.
22. Ahearn TS, Staff RT, Redpath TW, Semple SI. The use of the Levenberg-Marquardt curve-fitting algorithm in pharmacokinetic modelling of DCE-MRI data. Phys Med Biol 2005;50:N85-N92.
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
24. Morgan B, Utting JF, Higginson A, Thomas AL, Steward WP, Horsfield MA. A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging. Br J Cancer 2006;94:1420-1427.
25. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 2002;15:154-163.
26. Schmid VJ, Whitcher B, Padhani AR, Taylor NJ, Yang GZ. Bayesian methods for pharmacokinetic models in dynamic contrast-enhanced magnetic resonance imaging. IEEE Trans Med Imaging 2006;25:1627-1636.
27. Pellerin M, Yankeelov TE, Lepage M. Incorporating contrast agent diffusion into the analysis of DCE-MRI data. Magn Reson Med 2007;58:1124-1134.
28. Graff BA, Vangberg L, Rofstad EK. Quantitative assessment of uptake and distribution of iron oxide particles (NC100150) in human melanoma xenografts by contrast-enhanced MRI. Magn Reson Med 2004;51:727-735.
29. Graff BA, Kvinnsland Y, Skretting A, Rofstad EK. Intratumour heterogeneity in the uptake of macromolecular therapeutic agents in human melanoma xenografts. Br J Cancer 2003;88:291-297.
30. Bartolotta TV, Midiri M, Quaia E, et al. Liver haemangiomas undetermined at grey-scale ultrasound: contrast-enhancement patterns with SonoVue and pulse-inversion US. Eur Radiol 2005;15:685-693.
31. Bartolotta TV, Taibbi A, Galia M, et al. Centrifugal (inside-out) enhancement of liver hemangiomas: a possible atypical appearance on contrast-enhanced US. Eur J Radiol 2007;64:447-455.
32. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257.
33. Thelwall PE, Neves AA, Brindle KM. Measurement of bioreactor perfusion using dynamic contrast agent-enhanced magnetic resonance imaging. Biotechnol Bioeng 2001;75:682-690.
34. Reddy ST, Berk DA, Jain RK, Swartz MA. A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J Appl Physiol 2006;101:1162-1169.
35. Heilmann M, Kiessling F, Enderlin M, Schad LR. Determination of pharmacokinetic parameters in DCE MRI: consequence of nonlinearity between contrast agent concentration and signal intensity. Invest Radiol 2006;41:536-543.
36. Brookes JA, Redpath TW, Gilbert FJ, Murray AD, Staff RT. Accuracy of T1 measurement in dynamic contrast-enhanced breast MRI using two- and three-dimensional variable flip angle fast low-angle shot. J Magn Reson Imaging 1999;9:163-171.
37. Lauffer RB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. Chem Rev 1987;87:901-927.